CTOs on the Move


 
Freyr is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.freyrinc.com
  • 103 Carnegie Ctr Ste 300
    Princeton, NJ USA 08540
  • Phone: 908.345.5984

Executives

Name Title Contact Details

Similar Companies

JBJS

JBJS is a Needham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

HONOUR

HONOUR is a global leader in chemistry-driven solutions, focusing on the pharmaceutical, electronics, and performance materials industries. The company emphasizes innovation and agility, supported by a strong scientific workforce. HONOUR specializes in Custom Synthesis and Contract Development and Manufacturing Organization (CDMO) services, offering a range of customizable chemicals and ingredients, including coupling reagents, excipients, and polymer monomers. The Research & Development team at HONOUR combines advanced chemistry and technology to create practical solutions tailored to the unique needs of its partners. The company values trust and integrity in its relationships, aiming to foster sustainable progress in collaboration with its clients. HONOUR serves a diverse clientele, including pharmaceutical companies and electronics manufacturers, providing them with expert R&D capabilities and customized chemical solutions.

Epitopix

Epitopix is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orchard Therapeutics

Orchard Therapeutics is a leading global fully integrated commercial-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. These programs include Strimvelis®, the first autologous ex vivo gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), 2 other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline. The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles and Boston Children’s Hospital, and Telethon Institute of Gene Therapy/Ospedale San Raffaele. Orchard is a publicly traded company (NASDAQ: ORTX) with offices in the UK and the US, including London, San Francisco and Boston.